The place of SSRIs in the treatment of schizophrenia;La place des SSRIs dans le traitement de la schizophrénie

Encephale

Volumn 28, Issue 5 I, 2002, Pages 433-438

  Zullino, D ^a   Delacrausaz, P ^a   Baumann, P ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

Antipsychotic agents; Combination; Drug therapy; Schizophrenia; Serotonin reuptake inhibitors; Treatment outcome

Indexed keywords

BUTYROPHENONE DERIVATIVE; CITALOPRAM; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUOXETINE; FLUVOXAMINE; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

AGRANULOCYTOSIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEGATIVE SYNDROME; PATH ANALYSIS; POSITIVE SYNDROME; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

CLOZAPINE; HUMANS; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS;

EID: 17344386820     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Arndt S, Andreasen NC, Flaum M et al. A longitudinal study of symptoms dimensions in schizophrenia. Arch Gen Psychiatry 1995; 52: 352-60.
2. Bacher NM, Ruskin P. Addition of fluoxetine to treatment of schizophrenic patients. Am J Psychiatry 1991; 148: 274-5.
3. Balant Georgia AE, Ries C, Balant LP. Metabolic interaction between fluoxetine and clomipramine: A case report. Pharmacopsychiatry 1996; 29: 38-41.
4. Barnes TRE, Mac Evedy CJB, Nelson HE. Management of treatment resistant schizophrenia unresponsive to clozapine. Br J Psychiatry 1996; 169: 31-40.
5. Bouchard RH, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989; 146: 1352-3.
6. Boyer WR, Feighner JP. Safety and tolerability of selective serotonin re-uptake inhibitors. In: Feighneir JP, Boyer W, eds. Selective Serotonin Re-Uptake Inhibitors. Chichester: John Wiley & Sons, 1996.
7. Brunette MF, Muesner KT, Haiyi X et al. Relationships between symptoms of schizophrenia and substance abuse. J Nerv Ment Dis 1997; 185: 13-20.
8. Buchanan RW, Kirkpatrick B, Bryant N et al. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 1996; 153: 1625-7.
9. Carpenter WT. Serotonine-dopamine antagonists and treatment of negative symptoms. J Clin Psycopharmacol 1995; 15: 30S-35S.
10. D'Amato T, Dumas P, Saoud M et al. Interdépendance des symptômes positifs, négatifs et dépressifs au cours de la schizophrénie et chez des sujets dépourvus d'antécédents personnels de psychose. Encephale 1999; SP IV: 25-8.
11. Dobovsky SL, Thomas M. Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatry 1995; 56: 38-48.
12. Evins AE, Goff DC. Adjunctive antidepressant drug therapies in the treatment of negative symptoms of schizophrenia. CNS Drug 1996; 6: 130-47.
13. Gaebel W, Wolwer W. Problem der abgrenzung von Depression, Akenisie und Minussymptomatik mittels Beurteilungsskalen und Verhaltensbeobachtung: Messmethodisches Artefakt oder Ausdruck pathogenetischer Identität? in: Möller HJ, Laux G, eds. Fortschritte in der Diagnostik und Therapie Schizophrener Minus-symptomatik. Wien New York: Springer Verlag, 1994: 27-38.
14. Goff DC, Brotman AW, Waites M et al. Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 1990; 147: 492-4.
15. Goff DC, Midha KK, Sarid Degal O et al. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 1995; 117: 417-23.
16. Halman M, Goldbloom DS. Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry 1990; 28: 518-21.
17. Hamilton MS, Opler LA. Akathisia, suicidality and fluoxetine. J Clin Psychiatry 1992; 53: 401-6.
18. Haring C, Meise U, Humpel C etal. Dose-related plasma levels of clozapine: Influence of smoking behaviour, sex and age. Psychopharmacology 1989; 99: S38-S40.
19. Hiemke C, Weigman H, Härtter S et al. Elevated levels of clozapine in serum after addition of fluoxamine. J Clin Psychopharmacol 1994; 14: 279-81.
20. Iqbal n, Van Praag M. The role of serotonin in schizophrenia. Eur Neuropsychopharmacol 1995 (Suppl): 11-23.
21. Jerling M, Lindstrom L, Bondesson U et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368-74.
22. Kane JM. Factors which can make patients difficult to treat. Br J Psychiatry 1996; 169: 10-4.
23. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57: 449-54.
24. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 1999; 156: 1138-48.
25. Linnet K, Wiborg O. Influence of CYP2D6 polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. Ther Drug Monit 1996; 18: 629-34.
26. Lipinski JF, Mallya G, Zimmermann P et al. Fluoxetine-induced akathisia: Clinical and theoretical implications. J Clin Psychiatry 1989; 50 339-42.
27. Llerena A, Kiivet RA. Fixed combinations of neuroleptics with antidepressants: Potential risks and estimation of use. Br J Clin Pharmacol 1994; 37: 531-2.
28. Mauri MC, Bravin S, Fabiano L et al. Symptômes dépressifs et schizophrénie: Une approche psychopharmacologique. Encéphale 1995; 21: 355-8.
29. Müller Spahn F, Eich P, Hock C. The psychobiology of the acute schizophrenic episode. Int Clin Psychopharmacol 1996; 11: 19-28.
30. Newcomer JW, Faustman WO, Yeh W et al. Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia. Psychol Rep 1990; 31: 243-50.
31. Plasky P. Antidepressant usage in schizophrenia. Schizophr Bull 1991; 17: 649-57.
32. Preskorn SH. Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. Caddo: Professional Communications Inc, 1996.
33. Salokagas RKR. Structure of schizophrenic symptomatology and its changes over time: Prospective factor-analytical study. Acta Psychiatr Scand 1997; 95: 32-9.
34. Salokangas RKR, Saarijärvi S, Taiminent et al. Citalopram as an adjuvant in chronic schizophrenia: A double-blind placebocontrolled study. Acta Psychiatr Scand 1996; 94: 175-80.
35. Sanz Fuentenebro FJ, Huidobro A, TEJADAS Rivas A. Restless legs syndrome and paroxetine. Acta Psychiatr Scand 1996; 94: 482-4.
36. Silver H, Kaplan A, Jahjah N. Fluvoxamine augmentation for clozapine-resistant schizophrenia. Am J Psychiatry 1995; 152: 1098.
37. Silver H, Kaplan A, Kushnir M. Fluvoxamine augmentation in chronic schizophrenia: An open exploratory study. Hum Psychopharmacol 1995; 10: 59-63.
38. Silver H, Kaplan A, Kushnir M. Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study. Biol Psychiatry 1996; 40: 671-4.
39. Silver H, Nassar A. Fluvoxamine improves negative symptomes in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 1992; 31: 698-704.
40. Siris S, Bermanzohn PC, Gonzales A et al. The use of antidepressants for negative symptoms in a subset of schizophrenic patients. Psychopharmac Bull 1991; 27: 331-5.
41. Siris SG. Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. BrJ Psychiatry 1993; 163: 66-78.
42. Siris SG. Depression in schizophrenia: Perspective in the era of atypical antipsychotic agents. Am J Psychiatry 2000; 157: 1379-89.
43. Spina E, De Domenico P, Ruello C et al. Adjuntive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 1994; 9: 281-5.
44. Stein MH. Tardive dyskinesia in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1991; 148: 683.
45. Syvälathi EKG, Taiminen T, Saarijärvi S et al. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res 1997; 25: 24-32.
46. Taiminen T, Syvaläthi E, Saarijärvi S et al. Citalopram as an adjuvant in schizophrenia: Further evidence for a serotonergic dimension in schizophrenia. Int Clin Psychopharmacol 1997; 12: 31-5.
47. Tamminga CA, Holcomb HH, Gao WM et al. Glutamate pharmacology and the treatment of schizophrenia: Current status and future directions. Int Clin Psychopharmacol 1995; 10: 29-37.
48. Tate JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1989; 146: 399-400.
49. Thakore JH, Berti C, Dinan TG. An open trial of adjunctive sertraline in the treatment of chronic schizophrenia. Acta Psychiatr Scand 1996; 94: 194-7.
50. Vartiainen H, Tiihonen J, Putkonen A et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995; 91: 348-51.
51. WHO. World Health Report, 1995. Geneva: WHO, 1995.